This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.
RSA 318-B:48 · Possession of Ephedrine and Pseudoephedrine; Sale
318-B:48 Possession of Ephedrine and Pseudoephedrine; Sale. –
Copy linkNo person shall knowingly and unlawfully possess a drug product containing ephedrine, pseudoephedrine, or phenylpropanolamine with the intent to use the product as a precursor to manufacture methamphetamine or another controlled substance.
Copy linkA drug product containing ephedrine, pseudoephedrine, or phenylpropanolamine shall not be distributed at retail to the general public unless it is maintained in a locked display case or behind the counter out of the public's reach.
Copy link(a) A retail establishment shall not knowingly complete a sale to a person if the drug product or combination of drug products purchased would surpass a total of more than 3.6 grams within a 24-hour period or 9 grams within a 30-day period of ephedrine base, pseudoephedrine base, or phenylpropanolamine base or their isomers. The "base" form means the fraction of ephedrine, pseudoephedrine, or phenylpropanolamine present within a formulation containing a salt form of those respective drugs.
Copy linkThis section shall not apply to drug products dispensed pursuant to a valid prescription. Source. 2018, 124:1, eff. Jan. 1, 2019.
Copy linkSource note
Source. 2018, 124:1, eff. Jan. 1, 2019.
Source history
- 2018, 124:1, eff. Jan. 1, 2019
Related materials
Bill relationships
-
2026 HB1235
reference
es on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This section s
-
2026 HB1235-FN
reference
es on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This section s
-
2026 HB1237
reference
owledging the receipt and understanding of the policy. XXII. Excluding the drugs described in 49 C.F.R. section 392.4 of the federal Motor Carrier regulations and outlined under RSA 318-B, the only drugs that may be transported are those legally prescribed by a licensed physician, in their original container, and in the possession of the person who is prescribed them. XXIII. A tow business whose driver
-
2026 HB1423
amend · effective 2027-01-01
ffect without the invalid provision or application, and to this end the provisions of this act are declared to be severable. 3 New Subdivision; Synthetic Kratom Policy. Amend RSA 318-B by inserting after section 50 the following new subdivision: Synthetic Kratom Policy 318-B:51 Definitions. In this subdivision, "synthetic kratom" or "semisynthetic kratom" means: I. An alkaloid or alkaloid de
-
2026 HB1423-FN
amend · effective 2027-01-01
ffect without the invalid provision or application, and to this end the provisions of this act are declared to be severable. 3 New Subdivision; Synthetic Kratom Policy. Amend RSA 318-B by inserting after section 50 the following new subdivision: Synthetic Kratom Policy 318-B:51 Definitions. In this subdivision, "synthetic kratom" or "semisynthetic kratom" means: I. An alkaloid or alkaloid de
-
2026 HB1796
reference · effective 2027-01-01
arch, or arrest of a person or for a violation of probation or parole, and psilocybin that relates to the conduct is not contraband or subject to seizure or forfeiture pursuant to RSA 318-B: (a) A cultivator or provider possessing or transporting not more than an adequate supply of psilocybin for medical purposes as defined by department rule; and (b) A provider administering or a qualified patient t
-
2026 HB1796-FN
reference · effective 2027-01-01
arch, or arrest of a person or for a violation of probation or parole, and psilocybin that relates to the conduct is not contraband or subject to seizure or forfeiture pursuant to RSA 318-B: (a) A cultivator or provider possessing or transporting not more than an adequate supply of psilocybin for medical purposes as defined by department rule; and (b) A provider administering or a qualified patient t
-
2026 HB186
reference
of Drugs. Any person who drives on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This
-
2026 HB186-FN-A
amend
. 5 Model Drug Dealer Liability Act; Definition of Illegal Drug. Amend RSA 318-C:4, I to read as follows: I. "Illegal drug" means any drug which is a schedule I-IV drug under RSA 318-B, the possession, use, manufacture, sale, or transportation of which is not otherwise authorized by law. 6 New Chapter; Regulation of Cannabis. Amend RSA by inserting after chapter 318-E the following new chapter: CH
-
2026 HB194
reference · effective 2027-01-01
als under pharmacist supervision. A licensee or registrant of the board of pharmacy shall independently determine whether: (a) The act is expressly prohibited by: (1) This chapter; (2) The controlled drug act, RSA 318-B; (3) The rules of the board of pharmacy; or (4) Any other applicable state or federal laws or regulations; (b) The act is consistent with the individual's education, training, and experience; and (c) Performan
-
2026 HB194-FN
reference · effective 2027-01-01
licensee or registrant of the board of pharmacy shall independently determine whether: (a) The act is expressly prohibited by: (1) This chapter; (2) The controlled drug act, RSA 318-B; (3) The rules of the board of pharmacy; or (4) Any other applicable state or federal laws or regulations; (b) The act is consistent with the individual's education, training, and experience; and (c) Performance
-
2026 SB465
amend · effective 2027-01-01
s a schedule III controlled drug. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Controlled Drug Act; Xylazine. Amend RSA 318-B by inserting after section 1-c the following new section: 318-B:1-d Xylazine. I. Notwithstanding the provisions of RSA 318-B:1-a, relative to scheduling by rulemaking of the commissioner of the department of healt